Literature DB >> 19738068

Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1.

Chris Folkins1, Yuval Shaked, Shan Man, Terence Tang, Christina R Lee, Zhenping Zhu, Robert M Hoffman, Robert S Kerbel.   

Abstract

Cancer stem cells (CSC) are predicted to be critical drivers of tumor progression due to their self-renewal capacity and limitless proliferative potential. An emerging area of research suggests that CSC may also support tumor progression by promoting tumor angiogenesis. To investigate how CSC contribute to tumor vascular development, we used an approach comparing tumor xenografts of the C6 glioma cell line containing either a low or a high fraction of CSC. Compared with CSC-low tumors, CSC-high tumors exhibited increased microvessel density and blood perfusion and induced increased mobilization and tumor recruitment of bone marrow-derived endothelial progenitor cells (EPC). CSC-high C6 cell cultures also induced higher levels of endothelial cell proliferation and tubule organization in vitro compared with CSC-low cultures. CSC-high cultures and tumors expressed increased levels of the proangiogenic factors vascular endothelial growth factor and stromal-derived factor 1, and when signaling by either factor was blocked, all aspects of angiogenesis observed in CSC-high cultures and tumors, including microvessel density, perfusion, EPC mobilization/recruitment, and stimulation of endothelial cell activity, were reduced to levels comparable with those observed in CSC-low cultures/tumors. These results suggest that CSC contribute to tumor angiogenesis by promoting both local endothelial cell activity and systemic angiogenic processes involving bone marrow-derived EPC in a vascular endothelial growth factor-dependent and stromal-derived factor 1-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19738068      PMCID: PMC3409689          DOI: 10.1158/0008-5472.CAN-09-0167

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  SDF-1 activity on microvascular endothelial cells: consequences on angiogenesis in in vitro and in vivo models.

Authors:  F Mirshahi; J Pourtau; H Li; M Muraine; V Trochon; E Legrand; J Vannier; J Soria; M Vasse; C Soria
Journal:  Thromb Res       Date:  2000-09-15       Impact factor: 3.944

2.  Chemokines direct endothelial progenitors into tumor neovessels.

Authors:  Herbert Spring; Thomas Schüler; Bernd Arnold; Günter J Hämmerling; Ruth Ganss
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-02       Impact factor: 11.205

3.  Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment.

Authors:  Stefano Indraccolo; Laura Stievano; Sonia Minuzzo; Valeria Tosello; Giovanni Esposito; Erich Piovan; Rita Zamarchi; Luigi Chieco-Bianchi; Alberto Amadori
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

4.  Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth.

Authors:  D Lyden; K Hattori; S Dias; C Costa; P Blaikie; L Butros; A Chadburn; B Heissig; W Marks; L Witte; Y Wu; D Hicklin; Z Zhu; N R Hackett; R G Crystal; M A Moore; K A Hajjar; K Manova; R Benezra; S Rafii
Journal:  Nat Med       Date:  2001-11       Impact factor: 53.440

5.  Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.

Authors:  M Prewett; J Huber; Y Li; A Santiago; W O'Connor; K King; J Overholser; A Hooper; B Pytowski; L Witte; P Bohlen; D J Hicklin
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

6.  Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.

Authors:  Dan Lu; Juqun Shen; Marie D Vil; Haifan Zhang; Xenia Jimenez; Peter Bohlen; Larry Witte; Zhenping Zhu
Journal:  J Biol Chem       Date:  2003-08-12       Impact factor: 5.157

7.  Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.

Authors:  John M L Ebos; Jennifer Tran; Zubin Master; Daniel Dumont; Junia V Melo; Elisabeth Buchdunger; Robert S Kerbel
Journal:  Mol Cancer Res       Date:  2002-12       Impact factor: 5.852

8.  Tumor response to radiotherapy regulated by endothelial cell apoptosis.

Authors:  Monica Garcia-Barros; Francois Paris; Carlos Cordon-Cardo; David Lyden; Shahin Rafii; Adriana Haimovitz-Friedman; Zvi Fuks; Richard Kolesnick
Journal:  Science       Date:  2003-05-16       Impact factor: 47.728

9.  Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors.

Authors:  Marianna B Ruzinova; Rebecca A Schoer; William Gerald; James E Egan; Pier Paolo Pandolfi; Shahin Rafii; Katia Manova; Vivek Mittal; Robert Benezra
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

10.  Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells.

Authors:  Francesco Bertolini; Saki Paul; Patrizia Mancuso; Silvia Monestiroli; Alberto Gobbi; Yuval Shaked; Robert S Kerbel
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701

View more
  146 in total

Review 1.  Potential therapeutic implications of cancer stem cells in glioblastoma.

Authors:  Lin Cheng; Shideng Bao; Jeremy N Rich
Journal:  Biochem Pharmacol       Date:  2010-05-10       Impact factor: 5.858

Review 2.  Antiangiogenic therapies for glioblastoma.

Authors:  Isabel Arrillaga-Romany; Andrew D Norden
Journal:  CNS Oncol       Date:  2014

Review 3.  Chemoattractant receptors as pharmacological targets for elimination of glioma stem-like cells.

Authors:  Xiao-hong Yao; Ying Liu; Keqiang Chen; Wanghua Gong; Ming-yong Liu; Xiu-wu Bian; Ji Ming Wang
Journal:  Int Immunopharmacol       Date:  2011-09-17       Impact factor: 4.932

4.  Targeting the VEGF and PDGF signaling pathway in glioblastoma treatment.

Authors:  Alisa Madalina Popescu; Oana Alexandru; Corina Brindusa; Stefana Oana Purcaru; Daniela Elise Tache; Ligia Gabriela Tataranu; Citto Taisescu; Anica Dricu
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

5.  Bruceantin inhibits multiple myeloma cancer stem cell proliferation.

Authors:  Mark E Issa; Sarah Berndt; Gilles Carpentier; John M Pezzuto; Muriel Cuendet
Journal:  Cancer Biol Ther       Date:  2016-07-19       Impact factor: 4.742

6.  VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2.

Authors:  D Zhao; C Pan; J Sun; C Gilbert; K Drews-Elger; D J Azzam; M Picon-Ruiz; M Kim; W Ullmer; D El-Ashry; C J Creighton; J M Slingerland
Journal:  Oncogene       Date:  2014-08-25       Impact factor: 9.867

7.  The expression of P2X₇ receptors in EPCs and their potential role in the targeting of EPCs to brain gliomas.

Authors:  Jingqin Fang; Xiao Chen; Shunan Wang; Tian Xie; Xuesong Du; Heng Liu; Sumei Wang; Xue Li; Jinhua Chen; Bo Zhang; Huaping Liang; Yizeng Yang; Weiguo Zhang
Journal:  Cancer Biol Ther       Date:  2015-04-03       Impact factor: 4.742

8.  Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.

Authors:  William Cruz-Muñoz; Teresa Di Desidero; Shan Man; Ping Xu; Maria Luz Jaramillo; Kae Hashimoto; Catherine Collins; Myriam Banville; Maureen D O'Connor-McCourt; Robert S Kerbel
Journal:  Angiogenesis       Date:  2014-02-26       Impact factor: 9.596

9.  Ras-related protein Rap2c promotes the migration and invasion of human osteosarcoma cells.

Authors:  Jinxia Wu; Wenqi Du; Xiucun Wang; Lulu Wei; Yaojie Pan; Xiaojin Wu; Jinling Zhang; Dongsheng Pei
Journal:  Oncol Lett       Date:  2018-02-07       Impact factor: 2.967

10.  Curcumin inhibits the side population (SP) phenotype of the rat C6 glioma cell line: towards targeting of cancer stem cells with phytochemicals.

Authors:  Dunne Fong; Arthur Yeh; Rotem Naftalovich; Theresa Hyejeong Choi; Marion M Chan
Journal:  Cancer Lett       Date:  2010-01-20       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.